TickerTalks
Browse all tickers →
TickerTalks›$NVCT
NVNVCT

Nuvectis Pharma, Inc.

$NVCT·$537M·Biotechnology·Healthcare
$20.44-1.8%YTD+171.0%1Y+251.5%
Price updated 8m ago·X counts updated 2d ago
NVNVCT
$NVCTNuvectis Pharma, Inc.
$20.44-1.79%24 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $NVCT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

24X posts · last 7 days
Sep 11Sep 27
Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-07-08

Nuvectis Pharma is drawing attention almost entirely because of insider buying and a fresh price-target hike. Roth raised its target to $33 from $20, and the CEO and Chairman purchased roughly $250K of stock, with another director following on for a total of about $1.17M across two buys. One tracker also flagged a separate $916K open-market purchase from a large holder taking a position above 3.3M shares. Commentary reads as uniformly constructive, with no meaningful bearish counter-voice in the sample.

Read what X is saying about $NVCT

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NVCT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Too early to tellAcceleratingAI verdict · as of 2026-09-29

The move is getting stronger, with heavier trading behind it.

Nuvectis Pharma: +171% YTD, +252% TTM — CEO/Chairman/director bought $1.17M plus NXP200 got Breakthrough Therapy in China for glioma.

Nuvectis Pharma is the clinical-stage oncology biotech at $20.81 with $537M market cap. +171% YTD, +252% TTM as insider buying + Breakthrough Therapy Designation drive setup: Roth raised PT to $33 (from $20), CEO Bentsur + Chairman + director bought ~$1.17M combined. NXP200 got Breakthrough Therapy in China for BRAF V600-Mutant recurrent glioma.

The tension in one line:

  • Regulatory milestone specific: NXP200 Breakthrough Therapy Designation in China for BRAF V600-mutant recurrent/progressive high-grade glioma — a specific dated regulatory event that materially de-risks the timeline.
  • Insider buying material: CEO Bentsur + Chairman + director $1.17M combined open-market buys — at a small-cap $537M market cap, this is a specific management-conviction signal.
  • Fundamentals still pre-revenue: Q1 revenue $0, PE -18.7x (losses); 2027 analyst revenue $26M; the market cap is entirely on option-value of the NXP program.

The bull path is Nov 3 Q3 print (-$0.22 EPS est) plus specific NXP200 Phase III timeline commentary. The bear path is a Phase III timeline slip. BlackRock's new stake plus Roth PT hike to $33 add institutional confidence. S-3 shelf filed Aug 21 provides financing flexibility.

Agrees with X sentimentX sentiment is bullish on the specific insider buying (CEO + Chairman + director $1.17M combined) plus Roth PT hike to $33 (from $20) — fair given the NXP200 Breakthrough Therapy Designation and BlackRock's new stake. The +97% 3-month surge reflects the specific regulatory + insider catalysts converging.

What to watch: Nov 3 Q3 print (-$0.22 EPS est) — cash-runway disclosure, NXP200 Phase III trial-progress commentary, and any additional Breakthrough Therapy Designations. Continued insider buying patterns. S-3 shelf drawdown activity.

On the calendar: 2026-11-03 — Q3 earnings

insider buyingregulatory milestonelarge ytd move

Read the AI verdict on $NVCT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Oncology biotech developing NXP800, an HSF1 pathway inhibitor, and NXP900, a kinase inhibitor, for hard-to-treat solid tumors.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NVCT.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $NVCT

Partial — Oncology biotech developing NXP800, an HSF1 pathway inhibitor, and NXP900, a kinase inhibitor, for hard-to-treat solid tumors.

Top industry ETF

$IBBiShares Biotechnology ETF
+24.2%YTD
+48.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-18.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-199%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-148%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.30$-0.26-14.5%
Q1 2026May 5, 2026$-0.26$-0.30+13.3%
Q4 2025Feb 11, 2026$-0.31$-0.26-19.2%
Q3 2025Nov 4, 2025$-0.44$-0.24-83.3%
Next earningsTue, Nov 3·consensus EPS $-0.22

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.26$-6.5M
Q4 FY25$0———$-0.31$-4.0M
Q3 FY25$0———$-0.44$-4.5M
Q2 FY25$0———$-0.30$-3.4M

Forward consensus

5-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$3.0M$3.0M – $3.0M-$1.04-$1.09 – -$0.976
FY27$26.0M$26.0M – $26.0M-$1.15-$1.43 – -$0.866
FY28$4.4M$4.4M – $4.4M-$1.22-$1.72 – -$0.886
FY29$72.4M$72.4M – $72.4M-$0.24-$0.24 – -$0.244
FY30$215.3M$215.3M – $215.3M$2.81$2.81 – $2.813

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.64%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-3.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+57.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 17.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.265-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJun 30Mosseri Marlio Charles10% owner50.0K sh$916KBuyJun 30Ron BentsurCEO12.5K sh$250K
+ 5 other (5 awards) in window

See when $NVCT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

S-3Shelf registrationAug 21S-3
AI summary

Nuvectis Pharma, Inc. (NVCT, Fort Lee NJ), a clinical-stage oncology company developing targeted therapies, filed a shelf registration statement (Form S-3) on August 21, 2026, with CEO Ron Bentsur as contact and legal counsel Matthew Mamak at Alston & Bird. The S-3 authorizes future securities offerings for clinical development funding; the specific scope is in the full filing. Companion to the concurrent NVCT 8-K, suggesting active capital markets activity at this small-cap oncology company.

8-KMaterial agreementJun 308-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

Nuvectis Pharma entered an underwriting agreement with Cantor Fitzgerald for 5,000,000 shares at $20.00/share ($100M gross) plus a 30-day option for 750,000 additional shares; the prior close was $28.53. Material equity raise at approximately 30% discount to prior close.

424B5Prospectus supplement (offering)Jun 30424B5
AI summary

Nuvectis filed the prospectus supplement for the $20.00/share underwritten offering with a prior close of $28.53 on Nasdaq. Confirms the approximately 30% discount pricing for the NVCT equity offering.

424B5Prospectus supplement (offering)Jun 29424B5
AI summary

Nuvectis preliminary prospectus (dated June 29) for common stock at a price TBD, with a prior close of $27.19. Preliminary filing preceding the final $20.00 pricing.

8-KMaterial agreementJun 238-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

Nuvectis Pharma (NVCT) entered a material license agreement with Haisco Pharmaceutical Group on June 22, 2026, acquiring exclusive rights to develop, manufacture, and commercialize two drug candidates — NXP100 (Complement Factor B inhibitor HSK39297) and NXP200 (BRAF inhibitor HSK42360) — in all countries outside China/Asia-Pacific. Nuvectis will pay Haisco a $20M upfront payment plus up to $20M in early clinical milestones; Haisco is eligible for up to $1.4 billion in development, regulatory, and commercial milestone payments, plus high-single-digit to mid-teen royalties. Highly material — expands NVCT's pipeline into late-stage complement and BRAF oncology programs via a transformative licensing deal.

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
AI summary

Nuvectis Pharma (NVCT) held its 2026 Annual Meeting on June 11, 2026 with 60.8% of outstanding shares (16,193,686 of 26,614,628) represented. Class I director Ron Bentsur was re-elected (8,354,838 for / 391,265 against / 7,447,367 broker non-votes) and auditor Kesselman & Kesselman CPAs (PwC Israel) was ratified. A proxy statement correction reduced the reported outstanding shares from 27,668,036 to 26,614,628, but did not affect vote validity. Routine annual meeting governance disclosure.

+ 10 other (2 routine 8-Ks · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Gliomaglobenewswire.com·5d agoBlackRock Inc. Acquires New Stake in Nuvectis Pharma, Inc. $NVCTdefenseworld.net·26d agoNuvectis Pharma To Participate in Upcoming Investor Conferencesglobenewswire.com·26d agoNuvectis Stock Surges Around 97% in 3 Months: Here's Whyzacks.com·41d agoNuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlightsglobenewswire.com·56d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$NWBO$AURA$ARCT$IBRX$NKTR
Voices on X · last 7 days

No standout posts about $NVCT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport